Savaysa

There has been a revolution in the development of effective, small-molecule anticoagulants and antiplatelet agents. Numerous… (More)

Direct oral anticoagulants (DOACs) are in wide use among patients requiring both short- and long-term anticoagulation, mainly due… (More)

INTRODUCTION Atrial fi brillation (AF), the most common cardiac arrhythmia, is encountered in clinical practice with ever… (More)

C hr is B jo rn be rg / sc ie nc e so ur ce alfa, each experienced a 90–96% reversal of Eliquis activity within two to five… (More)

Edoxaban (Lixiana, Savaysa) is an oral, direct factor Xa inhibitor which has recently been approved for use in the treatment of… (More)

OBJECTIVE To evaluate the current literature and potential clinical role of edoxaban (Savaysa) for stroke prevention in… (More)

The development of venous thromboembolism is one of the major causes of morbidity and mortality in patients with cancer. The… (More)

For decades, the basis for anticoagulation therapy has been the inhibition of enzymes at various levels of the coagulation… (More)

Anticoagulant After a period of many decades during which warfarin (Coumadin— Bristol-Myers Squibb) was the standard of treatment… (More)